← Leaderboards
Robert J Glynn
Brigham And Women'S Hospital
$12,512,252
Attributed
$12,512,252
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,512,252 · 7
By mechanism
U01$6,558,799 · 1
R01$4,697,573 · 4
U24$862,130 · 1
R56$393,750 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Samia Mora$13,080,456
- Dariush Mozaffarian$28,150,783
- Paul M. Ridker$62,821,752
- James Kuang-Jan Liao$22,168,806
- Aruna Das Pradhan$4,705,538
Others in their field
Top investigators on “Venous Thrombosis”
- Paul M. Ridker · Brigham And Women'S Hospital$57,875,056
- Joel S. Bennett · University Of Pennsylvania$35,473,908
- John H Griffin · Scripps Research Institute$18,311,718
- Suresh Vedantham · Washington University$15,527,146
- Nicholas L Smith · University Of Washington$14,759,772
- Howard N Hodis · University Of Southern California$13,895,561
Research focus
Venous ThrombosisBaseWomanMyocardial InfarctionDesignCessation Of LifeParticipantThrombosisDeep Vein ThrombosisMalignant NeoplasmsLipidsPulmonary EmbolismRandomizedAnti-InflammatoryChronicClinical ResearchInterestEvaluationDiabetes MellitusFollow-UpPlayDiagnosisCardiovascular DiseasesCohort
Grant awards (24)
(2/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): DCC$862,130
U24 · FY2025 · HL · contact PI
Cardiovascular Inflammation Reduction Trial (CIRT): DCC$1,373,615
U01 · FY2016 · HL · contact PI
Cardiovascular Inflammation Reduction Trial (CIRT): DCC$1,428,182
U01 · FY2015 · HL · contact PI
Cardiovascular Inflammation Reduction Trial (CIRT): DCC$1,411,950
U01 · FY2014 · HL · contact PI
Cardiovascular Inflammation Reduction Trial (CIRT): DCC$1,198,942
U01 · FY2013 · HL · contact PI
Cardiovascular Inflammation Reduction Trial (CIRT): DCC$650,037
U01 · FY2012 · HL · contact PI
Cardiovascular Inflammation Reduction Trial (CIRT): DCC$496,073
U01 · FY2011 · HL · contact PI
Medication Use, Cormobidity and Outcomes in Aging Populations$319,646
R01 · FY2010 · AG · contact PI
Determinants of Venous Thromboembolism in Older People$220,041
R01 · FY2010 · AG · contact PI
Medication Use, Cormobidity and Outcomes in Aging Populations$322,875
R01 · FY2009 · AG · contact PI
Determinants of Venous Thromboembolism in Older People$222,264
R01 · FY2009 · AG · contact PI
Medication Use, Cormobidity and Outcomes in Aging Populations$322,875
R01 · FY2008 · AG · contact PI
Determinants of Venous Thromboembolism in Older People$222,264
R01 · FY2008 · AG · contact PI
Medication Use, Comorbidity and Outcomes in Aging populations$393,750
R56 · FY2007 · AG · contact PI
Determinants of Venous Thromboembolism in Older People$226,800
R01 · FY2007 · AG · contact PI
Medication Use, Comorbidity and Outcomes in Older People$389,250
R01 · FY2004 · AG
Epidemiology of Venous Thromboembolism$315,000
R01 · FY2004 · HL
Medication Use, Comorbidity and Outcomes in Older People$346,000
R01 · FY2003 · AG
Epidemiology of Venous Thromboembolism$315,000
R01 · FY2003 · HL
Medication Use, Comorbidity and Outcomes in Older People$345,167
R01 · FY2002 · AG
SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC$329,235
R01 · FY2002 · HL
Epidemiology of Venous Thromboembolism$315,625
R01 · FY2002 · HL
SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC$246,348
R01 · FY2001 · HL
SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC$239,183
R01 · FY2000 · HL